- This event has passed.
Employing Large-Scale Human Genetics for Therapeutic Target Discovery at 23andMe
January 16 @ 10:00 am - 11:00 am PST
Lino Gonzalez, Ph.D.
Senior Scientist, Therapeutics, 23andMe, Inc.
Wednesday, January 16th
10:00 – 11:00 a.m.
30 min Q&A to follow
Dr. Gonzales will present on his research at 23andMe and will also share the story of his educational and career journey.
23andMe, the leading personal genetics company, has accumulated a wealth of genotypic and phenotypic information from participants committed to improving human health through advances in genomics. 23andMe’s research platform is currently the world’s largest consented, re-contactable database for genetic research. This data will lead to a better understanding of the biological mechanisms of disease, and accelerate the discovery of novel treatments through human genetics. 23andMe’s Therapeutics Division was created in 2015 and is committed to discovering and developing novel therapies that can offer benefits for patients. This dedicated research and drug development group identifies novel targets using the 23andMe genetic database, generates lead compounds to these targets and performs preclinical research to support future clinical development. The team currently has research programs across several therapeutic areas, including oncology, skin, respiratory and cardiovascular disease. Dr. Gonzalez will provide an overview of the company’s approach to therapeutic development.
Lino Gonzalez is a Senior Scientist in the Therapeutics division at 23andMe, leading a team in the Protein Sciences. Prior to this, Lino worked for 15 years in the Protein Chemistry Department at Genentech and oversaw a Receptor Discovery Biochemistry group focused on the study of therapeutically important protein-receptor interactions. Lino received his B.S. in Chemistry from the University of California, Santa Barbara in 1991 and completed his Ph.D. at the University of California, Berkeley in 1996, studying the structural specificity of protein interactions. He did a postdoctoral fellowship at Stanford focusing on the structures and biochemical properties of neuronal membrane proteins involved in neurotransmitter release before joining Genentech in 2001. Lino has published over 30 peer reviewed scientific and review articles, which have garnered over 2,500 citations. In addition to his research, Lino has been a strong proponent for broadening participation in the STEM workforce. Lino is the current president of the Society for Advancement of Hispanics/Chicanos and Native Americans in Science (SACNAS).